Methadone vs Suboxone vs Naltrexone: How the Three Opioid Treatment Medications Compare

Three medications are FDA approved to treat opioid use disorder: methadone, buprenorphine (best known by the brand name Suboxone), and naltrexone (including the monthly injection Vivitrol). They are often discussed as if they were interchangeable. They are not. They act on the opioid system in three fundamentally different ways, they carry different rules, different commitments, and different tradeoffs, and each one fits a different kind of patient.

This page compares all three directly so you can walk into a clinical conversation understanding the real differences. It is educational information, not medical advice; the decision itself belongs with you and a qualified clinician, ideally guided by a structured evaluation such as the ASAM Criteria.

The Core Difference: Agonist, Partial Agonist, Antagonist

Every opioid medication is defined by what it does at the opioid receptor.

Methadone is a full opioid agonist. It fully activates opioid receptors, which is why it can eliminate withdrawal and craving even in people with very high tolerance, including fentanyl-level tolerance. Taken at a stable daily dose under supervision, it does not produce a high; it produces steadiness. It is a Schedule II controlled substance according to the DEA scheduling system, and for opioid use disorder it can only be dispensed through federally certified opioid treatment programs (OTPs).

Buprenorphine is a partial opioid agonist. It activates the same receptors but only partway, and its effect plateaus at higher doses, the so-called ceiling effect, which lowers overdose risk compared with full agonists. Suboxone combines buprenorphine with naloxone to discourage injection misuse. Since federal rules changed in 2023, any prescriber with a standard DEA registration can prescribe it; the old X-waiver is gone, which dramatically widened access through regular medical offices and telehealth.

Naltrexone is an opioid antagonist. It occupies opioid receptors without activating them at all. There is no opioid effect, no euphoria, and no physical dependence. If a person on naltrexone uses an opioid, the drug is blocked. The catch is the starting line: a person must be fully withdrawn from opioids, typically 7 to 14 days opioid free depending on the opioid involved, before starting naltrexone, or it will trigger sudden precipitated withdrawal. This is why naltrexone is usually paired with medically supervised detoxification first. Naltrexone is not a controlled substance.

Side-by-Side Comparison

Who Each Medication Tends to Fit

Methadone is often the strongest option for people with long, heavy opioid histories, very high tolerance, or repeated unsuccessful attempts on other medications. The structure of a daily clinic visit is a burden for some and a stabilizing routine for others. Research consistently shows methadone and buprenorphine reduce overdose death and all-cause mortality, which is why the CDC and NIDA treat them as first-line care for opioid use disorder.

Buprenorphine fits people who want effective medication with normal-life logistics: a prescription, a pharmacy, a monthly visit. Its ceiling effect makes it safer in overdose, though it can be less satisfying for people with extremely high fentanyl tolerance, and starting it requires being in early withdrawal to avoid precipitated withdrawal. Our full methadone and Suboxone treatment guide covers induction in detail.

Naltrexone fits a specific and often overlooked group: people who are physically dependent but do not want to remain on an opioid-based medication, people in safety-sensitive careers, people leaving controlled environments, and people whose primary issue is physical dependence rather than long-standing addiction. Understanding that distinction matters; the two conditions overlap but are not identical, a difference explained across our treatment types overview and in the educational resources at opiates.org. The tradeoff is the entry requirement: full detoxification first, which is safest done under medical supervision, whether in an outpatient taper or an inpatient setting.

What About Stopping?

There is no required endpoint for methadone or buprenorphine. Both may continue as long as they benefit the patient, and major health authorities warn that stopping agonist medication abruptly sharply raises overdose risk because tolerance falls. Any taper should be voluntary, gradual, clinician-supported, and paired with overdose prevention planning, including naloxone. Naltrexone has no taper because it creates no dependence; patients and clinicians simply decide together when protection is no longer needed.

One more point of clarity: detoxification by itself, by any method, is not complete treatment for opioid use disorder. And guidance from the CDC and the American Society of Addiction Medicine advises against anesthesia-assisted ultrarapid detoxification because of serious safety risks. Whatever path you consider, it should connect to ongoing care: medication, counseling, or both. Our guide on what to expect in treatment walks through how that plan takes shape, and how to pay for it.

Side Effects and Safety Profiles

All three medications are safe when prescribed and monitored, and all three have profiles worth knowing before the first appointment.

Methadone commonly causes constipation, sweating, drowsiness early in treatment, and reduced libido; less commonly it can affect heart rhythm (QT prolongation), which is why programs screen with an EKG when risk factors exist. Its most serious risk is overdose during the induction weeks or when combined with benzodiazepines or alcohol, which is exactly why dosing starts low and rises slowly under daily observation.

Buprenorphine shares the milder opioid side effects, constipation, headache, sweating, sleep changes, but its ceiling effect makes fatal overdose rare when taken alone. The characteristic hazard is precipitated withdrawal if it is started while a full agonist, especially fentanyl, still occupies the receptors; clinicians manage this with timing protocols and, increasingly, low-dose initiation schedules for fentanyl-exposed patients.

Naltrexone causes no dependence and no opioid effects; common side effects include nausea, headache, and injection-site reactions with Vivitrol, and it should not be started until liver function is confirmed adequate. Its defining risk is indirect: patients who discontinue naltrexone and return to use face a lowered tolerance, so every naltrexone plan should include overdose education and take-home naloxone.

One safety rule spans all three: combining any opioid, including methadone and buprenorphine, with benzodiazepines, alcohol, or other sedatives multiplies respiratory risk. Prescribers can manage combinations when they know about them, so full disclosure of every substance is a safety behavior, not a confession.

What Starting Each Medication Actually Looks Like

Starting methadone means enrolling at a certified opioid treatment program: an intake with medical history, examination, and drug screening, then a first dose the same day in many programs, followed by daily observed dosing while the dose is titrated upward over days to weeks. Take-home doses are earned over time under federal rules that were loosened in 2023 to allow earlier take-homes for stable patients.

Starting buprenorphine requires being in at least mild withdrawal, typically 12 to 48 hours after last use depending on the opioid, so the first dose relieves symptoms rather than triggering them. Many patients now complete induction at home under prescriber guidance after a telehealth visit; fentanyl-exposed patients may use gradual low-dose schedules instead. Once stabilized, treatment looks like ordinary medical care: prescriptions, pharmacy pickups, periodic visits, or a monthly Sublocade injection.

Starting naltrexone requires completing withdrawal entirely, which is the step most people underestimate. A medically supervised detoxification, inpatient or structured outpatient, bridges the gap safely, and the first dose is often preceded by a challenge test to confirm the receptors are clear. From there, it is a daily tablet or a monthly Vivitrol injection, with counseling carrying the behavioral side of recovery.

Whichever medication is chosen, pairing it with counseling, peer support, or structured therapy consistently outperforms medication alone in the research, and switching medications later is always an option; the first choice is a starting point, not a verdict.

Medication Plus Counseling: Why the Combination Wins

Every comparison of these three medications ends at the same junction: medication addresses the physiology, and something else has to address the rest. Physical dependence and opioid use disorder are related but distinct conditions, and the behavioral, psychiatric, and circumstantial dimensions of addiction do not dissolve because receptors are managed. In the research, medication paired with counseling, contingency management, peer support, or structured therapy consistently outperforms either component alone, both in retention and in outcomes.

What that looks like in practice varies by person: weekly therapy alongside a Suboxone prescription, the counseling built into a methadone program, an intensive outpatient program after detox and a first Vivitrol injection, or recovery community organizations layered onto any of the three. The point is not a specific formula; it is that the medication decision this page compares is one decision inside a larger plan, and programs that treat it that way get better results.

If this comparison leaves you between two options, that is a good outcome: it means you are ready for the conversation with a clinician that actually decides it, armed with the right questions about your tolerance, your history, your logistics, and your goals.

Frequently Asked Questions